To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
PINK1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PINK1, including heterozygous and homozygous P399L and A217D mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). *Heterozygous and homozygous L347P mutations are currently in development. Estimated Availability: Q1 2026.
TMEM175 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including heterozygous and homozygous M393T mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). *Heterozygous and homozygous Q65P mutations are currently in development. Estimated Availability: Q1 2026.
SNCA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SNCA, including heterozygous and homozygous A53T, A30P, E46K, and R219Q mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).
PRKN Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PRKN, including heterozygous and homozygous R275W, T240M, R42P, and P437L mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).
CLN3 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including heterozygous and homozygous R334H, heterozygous and homozygous V330I, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026
CTSB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CTSB for heterozygous and homozygous knockout. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).Estimated Availability: Q1 2026
LysoFQ-GBA FQ6 (Lysosomal GCase Probe Green)*
Assay
This GCase activity probe is a cell-permeable reporter for GCase activity, fluoresces upon glucocerebrosidase activation, facilitating the detection and monitoring of GBA1 activity. These probes were generated and kindly shared through the MJFF Sponsored Tools Program by David Vocadlo.
LysoFix-GBA FQ10 (Lysosomal GCase Probe Yellow)*
Assay
This GCase activity probe is a cell-permeable reporter for GCase activity, fluoresces upon glucocerebrosidase activation, facilitating the detection and monitoring of GBA1 activity. These probes were generated and kindly shared through the MJFF Sponsored Tools Program by David Vocadlo.
Alpha-Synuclein 1-119 Truncation Antibody
Antibody
Rabbit monoclonal antibody specific for human/mouse alpha-synuclein truncated at the 119 residue. The antibody is compatible with slot blot, ELISA, and immunocytochemistry applications.
Alpha-Synuclein 1-122 Truncation Antibody
Antibody
Rabbit monoclonal antibody specific for human/mouse alpha-synuclein truncated at the 122 residue. The antibody is compatible with slot blot and ELISA applications.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic